

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED

和 鉑 醫 藥 控 股 有 限 公 司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

**VOLUNTARY ANNOUNCEMENT
RESULTS FROM PORUSTOBART (HBM4003)
IN COMBINATION OF TORIPALIMAB IN PATIENTS WITH
HEPATOCELLULAR CARCINOMA AT ASCO 2023**

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the results of Phase Ib clinical trial of porustobart (HBM4003), in combination of toripalimab in patients with hepatocellular carcinoma (HCC) (trial code: NCT05149027) were published at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023.

Title: A Phase Ib Study of Porustobart (HBM4003), an anti-CTLA-4 Heavy Chain Only Monoclonal Antibody, in Combination with Toripalimab in Patients with Hepatocellular Carcinoma

Abstract Presentation Number: e16106

This is an open-label Phase Ib dose expansion study to evaluate the safety, tolerability, PK/PD and preliminary efficacy of HBM4003 in combination with toripalimab in patients with advanced HCC and other solid tumors.

Methods

Patients with advanced HCC (n=28) received porustobart 0.45 mg/kg plus toripalimab 240 mg every three weeks (Q3W) in both Cohort 1 and Cohort 2. Cohort 1 recruited patients who failed previous anti-VEGFR multikinase inhibitor(s) treatment while have not received anti-PD-(L)1 treatment (n=16); Cohort 2 recruited patients who failed previous anti-PD-(L)1 and anti-VEGF(R) treatments (n=12). The primary endpoint was objective response rate (ORR) per RECIST 1.1.

Results

As of 9 December 2022, 28 patients had been dosed. The median follow-up time was 3.6 months.

- HBM4003 in combination of toripalimab showed promising anti-tumor activity. PFS or OS data were not mature by the cut-off date.
 - In Cohort 1, the ORR and disease control rate (DCR) were 46.7% and 73.3%, respectively in 15 patients with post-treatment tumor assessments.
 - In Cohort 2, the ORR and DCR were 9.1% (18.2% per mRECIST) and 54.5%, respectively in 11 patients with post-treatment tumor assessments.
- HBM4003 in combination of toripalimab showed acceptable safety profile in HCC.
 - Treatment-related adverse events (TRAEs) were reported in 89.3% (25/28) patients, and Grade 3 TRAEs were reported in 39.3% (11/28) patients. No Grade 4 or Grade 5 TRAE was reported.
- HBM4003 in combination of toripalimab showed favorable PK/PD signature.
 - Porustobart promoted the clearance of Treg cells and the proliferation CD4⁺ and CD8⁺ T cell in periphery attested to its mechanism of action.
 - Greater effects were observed in Cohort 1, suggested a larger available pool of effectors to induce anti-tumor activity in the presence of effective Treg depletion.
 - No noticeable differences in PK between Cohort 1 and Cohort 2 were observed.

Conclusions

Porustobart 0.45 mg/kg plus toripalimab 240 mg Q3W showed promising anti-tumor activity and an acceptable safety profile in patients with advanced HCC.

About Porustobart

Porustobart is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from Harbour Mice[®]. It is the first heavy-chain-only monoclonal antibody globally. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, HBM4003 has demonstrated significantly improved depletion specific to high CTLA-4 Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combo-therapy.

Cautionary Statement: We cannot guarantee that we will be able to successfully develop or ultimately market any of our products referenced in this announcement. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 29 May 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive Directors.